Open an account Help & support Register Account summary Log out
Skip Header
Home Stock market news

Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

GSK files suit against AnaptysBio over licensing rights

Fri 21 Nov 2025 07:02

(Sharecast News) - GSK has filed a lawsuit against AnaptysBio in the US over licensing rights for its Jemperli cancer treatment. The suit, via GSK's Tesaro subsidiary, alleges a breach of the current agreement, with the UK pharma firm demanding a perpetual license to the drug - also known as dostarlimab - and halving royalties and milestone payments to AnaptysBio.

"Tesaro has initiated this litigation following allegations made by AnaptysBio that Tesaro has not fulfilled certain requirements of the license agreement entered in March 2014 and that AnaptysBio intends to revoke Tesaro's licence for dostarlimab. GSK and Tesaro are firmly of the view that these allegations are entirely without merit," GSK said in a statement on Friday.

Jemperli is currently approved in more than 35 countries for use in certain endometrial cancers, the most common gynaecologic cancer in the US.

GSK added that it had reported significant growth for Jemperli driven by label expansions in endometrial cancer, including in the US and EU.

"A robust and ambitious clinical trial programme to evaluate the potential use of dostarlimab in additional cancers, including rectal, colon and head and neck, is ongoing."

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

Fri 04 Sep 2026 12:27
BHP says it 'regularly explores options' after report Baowu eyeing iron ore mine stake
(Sharecast News) - BHP said on Friday that it "regularly explores options that may create long-term value to its shareholders" following a report that steelmaker China Baowu Steel Group is considering taking a stake in the company's Jimblebar iron ore mine in Western Australia.
Fri 04 Sep 2026 10:57
UK new car registrations jump as EV demand accelerates
(Sharecast News) - UK new car registrations rose sharply in August as demand for electric and hybrid vehicles strengthened, industry data revealed on Friday, although September is expected to provide a more meaningful test of underlying demand.
Fri 04 Sep 2026 10:57
JPMorgan reiterates 'overweight' on Prudential; cites cash conversion, buyback upside
(Sharecast News) - JPMorgan reiterated its 'overweight' rating on Prudential on Friday on cash conversion and buyback upside.
Fri 04 Sep 2026 09:19
Goldman upgrades Vodafone to 'buy', hikes price target
(Sharecast News) - Goldman Sachs upgraded Vodafone on Friday to 'buy' from 'sell' on higher relative returns and equity upside, despite its lower structural quality.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Awards

Award 1
Award 2
Award 3

Policies and important information

Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Statutory and Regulatory disclosures | Whistleblowing programme

Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document or Product Summary document which contains important information about the fund.

This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.

© FIL Limited 2026